BridgeBio Oncology Therapeutics (BBOT) Cash from Investing Activities (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Cash from Investing Activities of -$285.4 million for Q1 2026, down 3775.08% sequentially from $7.8 million in Q4 2025, and down 1957.15% YoY from $15.4 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Cash from Investing Activities (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Cash from Investing Activities for 3 years, with the latest figure at -$285.4 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 1957.15% year-over-year to -$285.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$236.7 million (down 400.26% YoY) and the FY2025 annual result came in at $73.3 million, up 160.84% from the prior year.
- Cash from Investing Activities fell to -$285.4 million in Q1 2026 per BBOT's latest filing, from $7.8 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $37.9 million in Q3 2024 and troughed at -$285.4 million in Q1 2026.
- A 3-year average of -$63.8 million and a median of $11.6 million in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 108.35% in 2025, then slumped 1957.15% in 2026.
- Over 3 years, Cash from Investing Activities stood at $25.6 million in 2024, then sank by 69.61% to $7.8 million in 2025, then tumbled by 3775.08% to -$285.4 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$285.4 million, $7.8 million, and $15.4 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 45.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.73 Mn |
| Jun 30, 2026 | 45.73 Mn |
| Mar 31, 2026 | -285.41 Mn |
| Mar 31, 2026 | -285.41 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Dec 31, 2025 | 7.77 Mn |
| Mar 31, 2025 | 15.37 Mn |
| Mar 31, 2025 | 15.37 Mn |
| Dec 31, 2024 | 25.56 Mn |
| Dec 31, 2024 | 25.56 Mn |
| Sep 30, 2024 | 37.91 Mn |
| Sep 30, 2024 | 37.91 Mn |
| Mar 31, 2024 | -184.00 Mn |
| Mar 31, 2024 | -184.00 Mn |